Chong Kun Dang

Excellent effect on high-risk patients: Chong Kun Dang announcing COVID-19 treatment

SEOUL: Chong Kun Dang, a South Korean pharmaceutical company, has announced that the effectiveness of COVID-19 treatment “Nafabeltan” at clinical trials has been proven. Nafabeltan is effective in treating COVID-19 patients with more severe conditions. “Nafabeltan has excellent treatment effects for high-risk patients,” an official from Chong Kun Dang said…

Read More »